Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review

Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery and development of new chemical entities (NCEs). It develops and markets branded and generic formulations. The companys formulations business encompasses therapeutic areas such as dermatology, respiratory and oncology. It has also presence in other therapeutic areas such as diabetes, cardiovascular and oral contraceptives. It also offers a wide range of specialty and generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark has manufacturing facilities in Argentina, the US, India and Czech Republic. The company markets its products in North America, Japan, Latin America, Europe, India, MENA, Asia and Russia, among others. Glenmark is headquartered in Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals Ltd Key Recent Developments

Jun 26,2020: Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY 2019-20
Dec 16,2019: Certificate Of compliance issued by The European Regulator, SUKL, Czech Republic for GlenmarkS Baddi manufacturing facility
Dec 16,2019: State Institute for Drug control Inspects Glenmark’s Baddi Manufacturing Facility in India
Nov 14,2019: Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
Oct 05,2019: Glenmark Pharmaceuticals: Update on the US FDA inspection of Glenmark’s Baddi manufacturing facility in Himachal Pradesh

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 

 
Section 1 - About the Company
Glenmark Pharmaceuticals Ltd - Key Facts
Glenmark Pharmaceuticals Ltd - Key Employees
Glenmark Pharmaceuticals Ltd - Key Employee Biographies
Glenmark Pharmaceuticals Ltd - Major Products and Services
Glenmark Pharmaceuticals Ltd - History
Glenmark Pharmaceuticals Ltd - Company Statement
Glenmark Pharmaceuticals Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Glenmark Pharmaceuticals Ltd - Business Description
Business Segment: API
Performance
Business Segment: Europe
Performance
Business Segment: India
Performance
Business Segment: Latin America
Performance
Business Segment: North America
Performance
Key Stats
Business Segment: Other Revenue
Performance
Business Segment: Rest of the World (ROW)
Performance
R&D Overview
Glenmark Pharmaceuticals Ltd - Corporate Strategy
Glenmark Pharmaceuticals Ltd - SWOT Analysis
SWOT Analysis - Overview
Glenmark Pharmaceuticals Ltd - Strengths
Glenmark Pharmaceuticals Ltd - Weaknesses
Glenmark Pharmaceuticals Ltd - Opportunities
Glenmark Pharmaceuticals Ltd - Threats
Glenmark Pharmaceuticals Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Jun 26, 2020: Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY 2019-20
Dec 16, 2019: Certificate Of compliance issued by The European Regulator, SUKL, Czech Republic for GlenmarkS Baddi manufacturing facility
Dec 16, 2019: State Institute for Drug control Inspects Glenmark’s Baddi Manufacturing Facility in India
Nov 14, 2019: Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
Oct 05, 2019: Glenmark Pharmaceuticals: Update on the US FDA inspection of Glenmark’s Baddi manufacturing facility in Himachal Pradesh
Oct 03, 2019: US FDA issues warning letter to Glenmark Pharmaceuticals
Aug 13, 2019: Glenmark’s consolidated revenue atRs.23,228.79 Mn.for Q1 FY 2019–20
May 07, 2019: Glenmark appoints Dr. Yasir Rawjee as chief executive officer of Glenmark Life Sciences, its subsidiary for the API business
Mar 28, 2019: Glenmark: Intimation of Appointment of Ms. Sona Saira Ramasastry as an Additional Director - independent Director
Mar 06, 2019: Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables

 
Glenmark Pharmaceuticals Ltd, Key Facts
Glenmark Pharmaceuticals Ltd, Key Employees
Glenmark Pharmaceuticals Ltd, Key Employee Biographies
Glenmark Pharmaceuticals Ltd, Major Products and Services
Glenmark Pharmaceuticals Ltd, History
Glenmark Pharmaceuticals Ltd, Other Locations
Glenmark Pharmaceuticals Ltd, Subsidiaries
Glenmark Pharmaceuticals Ltd, Key Competitors
Glenmark Pharmaceuticals Ltd, Ratios based on current share price
Glenmark Pharmaceuticals Ltd, Annual Ratios
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...1)
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...2)
Glenmark Pharmaceuticals Ltd, Interim Ratios
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures

 
Glenmark Pharmaceuticals Ltd, Performance Chart (2016 - 2020)
Glenmark Pharmaceuticals Ltd, Ratio Charts
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review

Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review market research report available in single user pdf license with Aarkstore Enterprise at USD 300

USD 300 View Report

Antidiarrhoeals Drugs Global Market Report 2020 Including: 1) By Drug Class: Mucosal Protectants, Motility Modifying Drugs 2) By Application: Adults, Childrens 3) By Type: OTC drugs, Prescription Drugs Covering: GlaxoSmithKline, Actelion, Perrigo, Lupin, Glenmark Pharmaceuticals

Antidiarrhoeals Drugs Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global antidiarrhoeals drugs market.Reasons

USD 4000 View Report

Actelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance Report

Actelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance ReportActelion Pharmaceuticals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review

Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review market research report available in single user pdf license with Aarkstore Enterprise at USD 300

USD 300 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available